Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Institut Gustave Roussy |
---|---|
Information provided by: | Institut Gustave Roussy |
ClinicalTrials.gov Identifier: | NCT00180830 |
The purpose of this study is to determine whether Glivec is effective, in children, adolescents and young adults, in the treatment of malignant disease in which evidence suggests a potential pathogenic role of one or more of the tyrosine kinases known to be inhibited by Glivec.
Condition | Intervention | Phase |
---|---|---|
Cancer |
Drug: Glivec Drug: Gleevec |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Open Label, Pilot Phase II Study of Glivec in Children and Adolescents With Life Threatening Diseases Known to Be Associated With One or More Glivec-Sensitive Tyrosine Kinases |
Ages Eligible for Study: | 6 Months to 21 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
France | |
Institut Gustave-Roussy | |
Villejuif, France, 94805 | |
Netherlands | |
Emma Kinderziekenhuis AMC | |
Amsterdam, Netherlands, 1100 DE | |
United Kingdom | |
Birmingham Children’s Hospital | |
Birmingham, United Kingdom, B4 6NH |
Study Chair: | Gilles Vassal, MD,PhD | Institut Gustave Roussy |
Study Chair: | Bruce Morland | Birmingham Children’s Hospital |
Study ID Numbers: | EGPS-01, CSET-2002/940, CSTI 571BFR10 |
Study First Received: | September 9, 2005 |
Last Updated: | September 7, 2006 |
ClinicalTrials.gov Identifier: | NCT00180830 |
Health Authority: | France: Afssaps - French Health Products Safety Agency; United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Imatinib |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses |
Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |